{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T05:12:59Z","timestamp":1788671579957,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clcc.2026.04.003","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T15:52:40Z","timestamp":1776959560000},"page":"340-351.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Matching-Adjusted Indirect Comparison of Sotorasib Plus Panitumumab Versus Trifluridine\/Tipiracil Plus Bevacizumab in Chemorefractory Metastatic Colorectal Cancer"],"prefix":"10.1016","volume":"25","author":[{"given":"Lisa","family":"Salvatore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan","family":"Fakih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutoshi","family":"Kuboki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik Paul","family":"Modest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy Jay","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cremolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0522-4961","authenticated-orcid":false,"given":"Istvan Matyas","family":"Majer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Rehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qui","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Pietrantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clcc.2026.04.003_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clcc.2026.04.003_bib0002","unstructured":"World Health Organization. Cancer. Available at: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cancer#:\u223c:text=colon%20and%20rectum%20(1.93%20million,stomach%20(1.09%20million%20cases. Accessed in May 24, 2024."},{"key":"10.1016\/j.clcc.2026.04.003_bib0003","doi-asserted-by":"crossref","unstructured":"Cancer.Net Editorial Board. Colorectal cancer: statistics. Available at: https:\/\/www.cancer.net\/cancer-types\/colorectal-cancer\/statistics. Accessed in May 24, 2024.","DOI":"10.1016\/S1533-0028(25)00011-8"},{"key":"10.1016\/j.clcc.2026.04.003_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejon.2019.101679","article-title":"High symptom burden is associated with impaired quality of life in colorectal cancer patients during chemotherapy: a prospective longitudinal study","volume":"44","author":"R\u00f6hrl","year":"2020","journal-title":"Eur J Oncol Nurs"},{"issue":"7","key":"10.1016\/j.clcc.2026.04.003_bib0005","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.3390\/cancers14071713","article-title":"Health-related quality of life in metastatic colorectal cancer patients treated with curative resection and\/or local ablative therapy or systemic therapy in the Finnish RAXO-study","volume":"14","author":"Lehtom\u00e4ki","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.clcc.2026.04.003_bib0006","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.prp.2009.07.010","article-title":"Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer","volume":"205","author":"Neumann","year":"2009","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.clcc.2026.04.003_bib0007","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Rectal Cancer V.1.2026\u00a9. National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed Accessed March 31, 2026. To view the most recent and complete version of the guideline, go online toNCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"key":"10.1016\/j.clcc.2026.04.003_bib0008","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Colon Cancer V.1.2026\u00a9. National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed March 31, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"issue":"1","key":"10.1016\/j.clcc.2026.04.003_bib0009","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"issue":"9863","key":"10.1016\/j.clcc.2026.04.003_bib0010","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.clcc.2026.04.003_bib0011","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clcc.2026.04.003_bib0012","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1200\/JCO.2017.74.3245","article-title":"Results of a randomized, double-blind, placebo-controlled, phase III trial of trifluridine\/tipiracil (TAS-102) monotherapy in Asian patients with previously treated metastatic colorectal cancer: the TERRA study","volume":"36","author":"Xu","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2026.04.003_bib0013","unstructured":"European Society for Medical Oncology. New indication concerns the third-line treatment of metastatic colorectal cancer in combination with bevacizumab. Available at: https:\/\/www.esmo.org\/oncology-news\/ema-recommends-extension-of-therapeutic-indications-for-trifluridine-tipiracil. Accessed in May 24, 2024."},{"key":"10.1016\/j.clcc.2026.04.003_bib0014","unstructured":"U.S. Food and Drug Administration. FDA approves trifluridine and tipiracil with bevacizumab for previously treated metastatic colorectal cancer. Available at: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-trifluridine-and-tipiracil-bevacizumab-previously-treated-metastatic-colorectal-cancer. Accessed in May 24, 2024."},{"issue":"18","key":"10.1016\/j.clcc.2026.04.003_bib0015","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","article-title":"Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer","volume":"388","author":"Prager","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clcc.2026.04.003_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102945","article-title":"Impact of KRAS(G12) mutations on survival with trifluridine\/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer: post hoc analysis of the phase III SUNLIGHT trial","volume":"9","author":"Tabernero","year":"2024","journal-title":"ESMO Open"},{"issue":"7781","key":"10.1016\/j.clcc.2026.04.003_bib0017","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"issue":"23","key":"10.1016\/j.clcc.2026.04.003_bib0018","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","article-title":"Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C","volume":"389","author":"Fakih","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clcc.2026.04.003_bib0019","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1380584","article-title":"KRAS G12C inhibitor combination therapies: current evidence and challenge","volume":"14","author":"Miyashita","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.clcc.2026.04.003_bib0020","series-title":"Matching-adjusted Indirect Treatment Comparisons of Sotorasib 960 mg Plus Panitumumab vs. Trifluridine\/Tipiracil Plus Bevacizumab in Chemorefractory Metastatic Colorectal Cancer","author":"Salvatore","year":"2024"},{"key":"10.1016\/j.clcc.2026.04.003_bib0021","series-title":"Overall Survival (OS) of Phase 3 CodeBreaK 300 Study of Sotorasib Plus Panitumumab (Soto+Pani) Versus Investigator\u2019s Choice of Therapy for KRAS G12C-mutated Metastatic Colorectal Cancer (mCRC)","author":"Fakih","year":"2024"},{"key":"10.1016\/j.clcc.2026.04.003_bib0022","series-title":"Overall Survival (OS) of Phase 3 CodeBreaK 300 Study of Sotorasib Plus Panitumumab (Soto+Pani) Versus Invesigator\u2019s Choice of Therapy for KRAS G12C-mutated Metastatic Colorectal Cancer (mCRC)","author":"Fakih","year":"2024"},{"issue":"1","key":"10.1016\/j.clcc.2026.04.003_bib0023","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41591-023-02717-6","article-title":"Sotorasib with panitumumab in chemotherapy-refractory KRAS(G12C)-mutated colorectal cancer: a phase 1b trial","volume":"30","author":"Kuboki","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.clcc.2026.04.003_bib0024","series-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.4. Chichester, UK: John Wiley & Sons","author":"Higgins","year":"2023"},{"issue":"6","key":"10.1016\/j.clcc.2026.04.003_bib0025","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1136\/jech.52.6.377","article-title":"The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions","volume":"52","author":"Downs","year":"1998","journal-title":"J Epidemiol Community Health"},{"key":"10.1016\/j.clcc.2026.04.003_bib0026","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.clcc.2026.04.003_bib0027","unstructured":"Centre for Reviews and Dissemination. Systematic Reviews. CRD\u2019s guidance for undertaking reviews in health care. Available at: https:\/\/www.york.ac.uk\/media\/crd\/Systematic_Reviews.pdf. Accessed in August 6, 2024."},{"key":"10.1016\/j.clcc.2026.04.003_bib0028","author":"Data on File","year":"2023"},{"issue":"6","key":"10.1016\/j.clcc.2026.04.003_bib0029","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","article-title":"Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research","volume":"15","author":"Signorovitch","year":"2012","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.clcc.2026.04.003_bib0030","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s40273-015-0271-1","article-title":"Simulation and matching-based approaches for indirect comparison of treatments","volume":"33","author":"Ishak","year":"2015","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clcc.2026.04.003_bib0031","series-title":"NICE DSU Technical Support Document 18: Methods for Population-Adjusted Indirect Comparisons in Submissions to NICE","author":"Phillippo","year":"2016"},{"issue":"12","key":"10.1016\/j.clcc.2026.04.003_bib0032","doi-asserted-by":"crossref","first-page":"E3648","DOI":"10.3390\/cancers12123648","article-title":"A matching-adjusted indirect comparison of pembrolizumab + chemotherapy vs. nivolumab + ipilimumab as first-line therapies in patients with PD-L1 TPS \u22651% metastatic NSCLC","volume":"12","author":"Halmos","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clcc.2026.04.003_bib0033","unstructured":"National Institute for Healthcare and Excellence. Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer. Available at: https:\/\/www.nice.org.uk\/guidance\/ta781. Accessed May 24, 2024."},{"key":"10.1016\/j.clcc.2026.04.003_bib0034","doi-asserted-by":"crossref","first-page":"S444","DOI":"10.1016\/j.jval.2019.09.246","article-title":"Indirect comparison of HRQOL data for patients with treatment-refractory metastatic colorectal cancer treated with trifluridine & tipiracil (PRECONNECT trial) compared with BSC & regorafenib (CORRECT trial)","volume":"22","author":"Moreno","year":"2019","journal-title":"Value Health"},{"key":"10.1016\/j.clcc.2026.04.003_bib0035","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"10","key":"10.1016\/j.clcc.2026.04.003_bib0036","doi-asserted-by":"crossref","first-page":"935","DOI":"10.2165\/11538370-000000000-00000","article-title":"Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept","volume":"28","author":"Signorovitch","year":"2010","journal-title":"Pharmacoeconomics"},{"issue":"16_suppl","key":"10.1016\/j.clcc.2026.04.003_bib0037","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1200\/JCO.2023.41.16_suppl.3560","article-title":"Matching-adjusted indirect treatment comparisons (MAIC) of sotorasib vs trifluridine\/tipiracil (T\/T) and regorafenib as monotherapy in chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC)","volume":"41","author":"Price","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2026.04.003_bib0038","series-title":"R: A Language and Environment for Statistical Computing","year":"2010"},{"issue":"1","key":"10.1016\/j.clcc.2026.04.003_bib0039","doi-asserted-by":"crossref","DOI":"10.1101\/2024.04.01.24305158","article-title":"Postprogression therapy and confounding for the estimated treatment effect on overall survival in phase III oncology trials","volume":"3","author":"Sherry","year":"2024","journal-title":"BMJ Oncol"},{"issue":"9","key":"10.1016\/j.clcc.2026.04.003_bib0040","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S1470-2045(25)00352-3","article-title":"Health-related quality of life in patients with KRAS(G12C)-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial","volume":"26","author":"Modest","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2026.04.003_bib0041","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/onco.13870","article-title":"The prognostic impact of KRAS G12C mutation in patients with metastatic colorectal cancer: a multicenter retrospective observational study","volume":"26","author":"Chida","year":"2021","journal-title":"Oncologist"},{"issue":"17","key":"10.1016\/j.clcc.2026.04.003_bib0042","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17172803","article-title":"KRAS G12C inhibition in solid tumors: biological breakthroughs, clinical evidence, and open challenges","volume":"17","author":"Vitiello","year":"2025","journal-title":"Cancers (Basel)"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002826000265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002826000265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T04:23:35Z","timestamp":1788668615000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002826000265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1533002826000265"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2026.04.003","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Matching-Adjusted Indirect Comparison of Sotorasib Plus Panitumumab Versus Trifluridine\/Tipiracil Plus Bevacizumab in Chemorefractory Metastatic Colorectal Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2026.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}